The arrangements for the funding and supply of Red Cell Diagnostic Products (RCDP) to public laboratories under existing standing offer contracts which are managed by the National Blood Authority (NBA) will cease from 1 December 2023. This will enable jurisdictions and laboratories to make direct arrangements with suppliers to purchase these products required to manage the services of their own laboratories.
Access to products from 1 December 2023
Laboratories and jurisdictions requiring RCDP will need to establish arrangements directly with suppliers to enable continued supply. These new arrangements will need to be in place from 1 December 2023. This may be through your hospital or health department network or directly with suppliers.
Suppliers that are covered by the existing arrangements include:
- Grifols Australia
- Ortho-Clinical Diagnostics
- Paragon Care (Immulab)
- Bio-Rad Laboratories